109 related articles for article (PubMed ID: 38759836)
1. Cellular landscape of adrenocortical carcinoma at single-nuclei resolution.
Tourigny DS; Altieri B; Secener KA; Sbiera S; Schauer MP; Arampatzi P; Herterich S; Sauer S; Fassnacht M; Ronchi CL
Mol Cell Endocrinol; 2024 Sep; 590():112272. PubMed ID: 38759836
[TBL] [Abstract][Full Text] [Related]
2. Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.
Simon DP; Hammer GD
Mol Cell Endocrinol; 2012 Mar; 351(1):2-11. PubMed ID: 22266195
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
4. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
5. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
6. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
7. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.
Gara SK; Wang Y; Patel D; Liu-Chittenden Y; Jain M; Boufraqech M; Zhang L; Meltzer PS; Kebebew E
Nucleic Acids Res; 2015 Oct; 43(19):9327-39. PubMed ID: 26446994
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
[TBL] [Abstract][Full Text] [Related]
9. Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
J Cell Mol Med; 2021 Nov; 25(21):10061-10072. PubMed ID: 34664400
[TBL] [Abstract][Full Text] [Related]
10. Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.
Pereira SS; Máximo V; Coelho R; Batista R; Soares P; Guerreiro SG; Sobrinho-Simões M; Monteiro MP; Pignatelli D
J Cell Biochem; 2017 Aug; 118(8):2064-2071. PubMed ID: 27886397
[TBL] [Abstract][Full Text] [Related]
11. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.
Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B
Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380
[TBL] [Abstract][Full Text] [Related]
12. Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
Xu C; Qin C; Jian J; Peng Y; Wang X; Chen X; Wu D; Song Y
Immun Inflamm Dis; 2022 Sep; 10(9):e680. PubMed ID: 36039643
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
14. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C
Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525
[TBL] [Abstract][Full Text] [Related]
15. CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle.
Huang YG; Li D; Wang L; Su XM; Tang XB
J Transl Med; 2022 Feb; 20(1):78. PubMed ID: 35123514
[TBL] [Abstract][Full Text] [Related]
16. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
17. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
[TBL] [Abstract][Full Text] [Related]
18. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
Cheng JY; Brown TC; Murtha TD; Stenman A; Juhlin CC; Larsson C; Healy JM; Prasad ML; Knoefel WT; Krieg A; Scholl UI; Korah R; Carling T
BMC Cancer; 2017 Mar; 17(1):164. PubMed ID: 28249601
[TBL] [Abstract][Full Text] [Related]
19. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
20. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
